The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity

Vlasios Brakoulias

doi:10.1517/14656566.2014.924506

The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity

Vlasios Brakoulias

Western Sydney University

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Pharmacological treatments currently available to treat obsessive-compulsive disorder (OCD) rarely produce remission. This Editorial aims to encourage more targeted research based on the specific OCD symptoms patients primarily present with. Specific OCD symptoms have been associated with distinct clinical characteristics, aetiological hypotheses and treatment responses. Treatment studies should use these findings to develop more targeted pharmacotherapy for patients with OCD.

Original language	English
Pages (from-to)	1321-1323
Number of pages	3
Journal	Expert Opinion on Pharmacotherapy
Volume	15
Issue number	10
DOIs	https://doi.org/10.1517/14656566.2014.924506
Publication status	Published - 2014

Keywords

chemotherapy
obsessive-compulsive disorder
therapeutics

Access to Document

10.1517/14656566.2014.924506

Cite this

@article{d17e913ebb6642bdb5d5d883458d9056,

title = "The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity",

abstract = "Pharmacological treatments currently available to treat obsessive-compulsive disorder (OCD) rarely produce remission. This Editorial aims to encourage more targeted research based on the specific OCD symptoms patients primarily present with. Specific OCD symptoms have been associated with distinct clinical characteristics, aetiological hypotheses and treatment responses. Treatment studies should use these findings to develop more targeted pharmacotherapy for patients with OCD.",

keywords = "chemotherapy, obsessive-compulsive disorder, therapeutics",

author = "Vlasios Brakoulias",

year = "2014",

doi = "10.1517/14656566.2014.924506",

language = "English",

volume = "15",

pages = "1321--1323",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1744-7666",

publisher = "Taylor & Francis",

number = "10",

}

TY - JOUR

T1 - The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity

AU - Brakoulias, Vlasios

PY - 2014

Y1 - 2014

N2 - Pharmacological treatments currently available to treat obsessive-compulsive disorder (OCD) rarely produce remission. This Editorial aims to encourage more targeted research based on the specific OCD symptoms patients primarily present with. Specific OCD symptoms have been associated with distinct clinical characteristics, aetiological hypotheses and treatment responses. Treatment studies should use these findings to develop more targeted pharmacotherapy for patients with OCD.

AB - Pharmacological treatments currently available to treat obsessive-compulsive disorder (OCD) rarely produce remission. This Editorial aims to encourage more targeted research based on the specific OCD symptoms patients primarily present with. Specific OCD symptoms have been associated with distinct clinical characteristics, aetiological hypotheses and treatment responses. Treatment studies should use these findings to develop more targeted pharmacotherapy for patients with OCD.

KW - chemotherapy

KW - obsessive-compulsive disorder

KW - therapeutics

UR - http://handle.westernsydney.edu.au:8081/1959.7/uws:50651

U2 - 10.1517/14656566.2014.924506

DO - 10.1517/14656566.2014.924506

M3 - Article

SN - 1744-7666

SN - 1465-6566

VL - 15

SP - 1321

EP - 1323

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 10

ER -

The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this